GlassScriptPhysician profile
Hardeep Gill
NPI 1245490523
$3,422.65
in general payments reported to CMS, 2019-2025
34 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $31.96 · 2021: $179 · 2022: $278 · 2023: $678 · 2024: $690 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.01 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $332.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $326.68 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $283.01 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $207.09 | 2022-2025 | |
| Dexcom, INC. | $156.63 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $150.92 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $148.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $148.06 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.10 | 2024-2025 | |
| Abbott Laboratories | $115.57 | 2021-2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $83.02 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $69.42 | 2019 | |
| Astellas Pharma US INC | $65.04 | 2019-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $64.63 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.14 | 2019-2025 | Jardiance |
| Inspire Medical Systems, INC. | $63.21 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $55.50 | 2024-2025 | Nuzyra |
| Eisai INC. | $50.14 | 2023-2025 | |
| Esperion Therapeutics, INC. | $46.84 | 2021 | |
| Merck Sharp & Dohme LLC | $45.23 | 2019-2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.25 | 2019 | |
| Sanofi Pasteur INC. | $36.58 | 2022 | |
| Ibsa Pharma INC. | $35.42 | 2019-2025 | Flector, Licart, Tirosint |
| Kowa Pharmaceuticals America, INC. | $34.49 | 2024-2025 | Zoryve |
| Irhythm Technologies, INC. | $32.37 | 2023 | Zio Xt Patch |
| Abiomed | $30.76 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.33 | 2019 | |
| Daiichi Sankyo INC. | $20.76 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.90 | 2022 | |
| Currax Pharmaceuticals LLC | $16.58 | 2025 | Contrave |
| Genentech USA, INC. | $14.36 | 2019 | |
| Allergan, INC. | $12.49 | 2019 | |
| Assertio Therapeutics, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardeep Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.